novartis ag-sponsored adr
(NOTA:German Stock Exchange)
Transactions by NOVARTIS AG-SPONSORED ADR (NOTA) in the last 6 months
Intellia Therapeutics Inc. announced that it has received $70 million in its series B round of funding led by a new investor, OrbiMed Advisors, L.L.C. on September 1, 2015. The transaction included participation from new investors, Fidelity Management & Research Company, Foresite Capital Management, LLC, Sectoral Asset Management Inc, Ecor1 Capital, LLC, Janus Capital Management LLC, existing investors, Atlas Venture L.P., Novartis AG, and other leading mutual fund and ...
Ecor1 Capital, LLC
Fidelity Management & Research Company
Foresite Capital Mangement, LLC
Janus Capital Management LLC
OrbiMed Advisors, L.L.C.
Sectoral Asset Management Inc
Mereo BioPharma Group Limited acquired Three Innovative Clinical-Stage Development Programmes of Novartis AG (SWX:NOVN) in stock on July 29, 2015. The consideration will be paid by issuing share in Mereo. In addition Novartis will share in the success of the development of these compounds, including a share on milestones and royalties on future commercial sales. Robert Cantone, Daryn Grossman, Mary Consalvi, Daniel St. Onge, Julie Kim and Laura Goldsmith of Proskauer ...
Novartis AG (SWX:NOVN) agreed to acquire an unknown stake in Mereo BioPharma Group Limited on July 29, 2015. It will swap of clinical assets for equity with Mereo BioPharma Group Ltd. The deal involves compounds in areas of unmet medical need including BPS-804, to improve bone density in brittle bone syndrome, an orphan disease; BCT-197 for acute exacerbations in COPD, and BGS-649 for obese men with hypogonadotrophic hypogonadism to normalize testosterone levels. Under ...
Aduro BioTech, Inc. announced that it has received $25 million in a round of funding from new investor Novartis AG on March 30, 2015. As a result of the transaction, the investor has acquired 2.7% stake in the company. The investor has also committed to invest another $25 million at a future date,
GlaxoSmithKline plc (LSE:GSK) acquired 4.96% stake in Valneva SE (ENXTPA:VLA) from Novartis AG (SWX:NOVN) on March 3, 2015.
|Gilead Sciences Inc||$104.63 USD||+0.36|
|Johnson & Johnson||$93.88 USD||+0.53|
|Merck & Co Inc||$53.38 USD||+0.40|
|Nestle SA||SFr.71.05 CHF||+0.75|
|View Industry Companies|